# Pancreatic ductal adenocarcinoma

Source: https://onco.cc/cancers/pancreatic/  
OnCo record `pancreatic` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change.

## Summary

Pancreatic ductal adenocarcinoma is defined by late presentation, a near-universal KRAS mutation (G12D ~40%, G12V ~30%, G12R ~15%, G12C ~1-2%; ~10% KRAS-wild-type with actionable fusions in NRG1, NTRK, ALK, or BRAF), a desmoplastic stroma that occupies most of the tumour, and an immunologically cold microenvironment. Surgery is the only cure and only ~20% of patients present resectable; five-year survival remains ~13% overall but exceeds 40% for resected patients who complete adjuvant mFOLFIRINOX.

For thirty years the story was chemotherapy: gemcitabine (1997), FOLFIRINOX (2011), gemcitabine/nab-paclitaxel (2013), adjuvant mFOLFIRINOX (PRODIGE 24, 2018), NALIRIFOX (2024), with olaparib maintenance for germline BRCA carriers (POLO, 2019) and zenocutuzumab for NRG1 fusions (2024) as the only biomarker-directed drugs. 2026 changed the trajectory. Optune Pax tumour treating fields were approved for locally advanced disease (PANOVA-3). Daraxonrasib, a pan-RAS(ON) inhibitor, nearly doubled overall survival in previously treated metastatic disease in RASolute 302 (13.2 vs 6.7 months, HR 0.40), presented in the ASCO 2026 plenary with simultaneous NEJM publication; regulatory filing is expected under a national priority voucher. The G12D-selective zoldonrasib, combined with daraxonrasib or with chemotherapy, produced response rates never before seen in this disease.

What remains unsolved: detection (no screening outside high-risk surveillance; MCED tests and new-onset-diabetes enrichment are the leading ideas), the stroma and immune exclusion that have defeated every checkpoint inhibitor trial, resistance to RAS inhibitors (already emerging), and the fact that half of patients are too frail for the most effective regimens. The most promising directions are RAS inhibitors moving into first line and neoadjuvant settings, personalised (autogene cevumeran) and shared-antigen (ELI-002 7P) vaccines in the adjuvant setting despite AMPLIFY-7P's miss, CLDN18.2 and FAP-directed delivery, and blood-based early detection.

## Fields

- Kind: Cancer
- Last checked: 2026-09-06
- Tags: gi; spike
- Group: gastrointestinal
- Burden: Pancreatic cancer causes about 500,000 cases per year. Surgery followed by mFOLFIRINOX cures a meaningful share of the ~20% found early, high-risk surveillance now finds most cancers in carriers at stage I, and the first RAS inhibitor, daraxonrasib, delivered the biggest result in the disease's history in advanced disease (RASolute 302, 2026). Five-year survival is about 13% overall and above 40% for resected patients who complete adjuvant chemotherapy; on current trends it will be the second most common cause of cancer death in the US by 2030.
- Subtypes: Classical (GATA6-high, better prognosis, more chemosensitive); Basal-like / squamous (GATA6-low, chemotherapy-resistant); KRAS-wild-type (~10%; NRG1, NTRK, ALK, BRAF fusions; MSI-H); Germline-driven (BRCA2, PALB2, ATM, CDKN2A, STK11); Pancreatic neuroendocrine tumours (a different disease; see neuroendocrine)
- Biomarkers: KRAS (G12D 40%, G12V 30%, G12R 15%, G12C 1-2%); Germline BRCA/PALB2; MSI (rare); NRG1 fusions (KRAS-wild-type); CLDN18.2; CA19-9; CA 19-9 (prognosis and monitoring); KRAS mutation subtype (G12D/V/R/C; wild-type triggers fusion testing); Germline panel (BRCA1/2, PALB2, ATM, CDKN2A, STK11, Lynch); HRD / platinum sensitivity; GATA6 (classical vs basal-like); ctDNA (KRAS-mutant cfDNA) for MRD and response; FAPI PET avidity (investigational); CLDN18.2 IHC (trials)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/pancreatic/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/pancreatic/#overview [11 subtypes, 8 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/pancreatic/#what-it-is [16 subtypes, 5 sites of spread]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/pancreatic/#finding-it [14 biomarkers, 11 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/pancreatic/#treating-it [5 settings, 9 regimens, 4 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/pancreatic/evidence/ [163 trials, 47 key papers, 17 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/pancreatic/science/ [114 targets, 13 pathways, 9 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/pancreatic/where-you-are/ [43 centres]
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/pancreatic/#living-with-it [23 questions, 2 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/pancreatic/coming/ [80 medicines, 162 trials, 61 ideas, 10 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/pancreatic/data/ [812 connected records]

## Standard of care

- High-risk surveillance: Annual MRI/MRCP or EUS for germline carriers and familial kindreds (CAPS/PRECEDE); germline testing for every diagnosed patient and first-degree relatives. ([High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [MRI](https://onco.cc/technologies/mri/), [PRECEDE](https://onco.cc/trials/precede/))
- Resectable / borderline: Neoadjuvant mFOLFIRINOX (borderline; increasingly resectable), surgery, then adjuvant mFOLFIRINOX to complete ~6 months (PRODIGE 24); gemcitabine/capecitabine if unfit. Chemoradiation selectively (PREOPANC). ([FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [PREOPANC-1 / PREOPANC-2](https://onco.cc/trials/preopanc/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/))
- Locally advanced unresectable: FOLFIRINOX or gem/nab-paclitaxel; TTFields with gem/nab-paclitaxel (Optune Pax, 2026); SBRT or MR-guided ablative radiotherapy; IRE in selected centres; reassess for conversion surgery. ([PANOVA-3](https://onco.cc/trials/panova-3/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/))
- Metastatic, first line: mFOLFIRINOX or NALIRIFOX (fit) or gemcitabine/nab-paclitaxel; olaparib maintenance if gBRCA after ≥16 weeks platinum; zenocutuzumab if NRG1 fusion; pembrolizumab if MSI-H; trials of RAS inhibitors + chemotherapy. ([NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/), [NAPOLI 3](https://onco.cc/trials/napoli-3/), [POLO](https://onco.cc/trials/polo/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/))
- Metastatic, second line: Daraxonrasib once approved (RASolute 302: OS 13.2 vs 6.7 months) is expected to become the standard; otherwise switch backbone (gem/nab-pac after FOLFIRINOX, or liposomal irinotecan/5-FU after gemcitabine). ([RASolute 302](https://onco.cc/trials/rasolute-302/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/))

## State of the art

- First TTFields approval (2026).
- Pan-RAS inhibitors with unprecedented OS in phase 1/2.
- Personalised vaccines with durable immunity.
- RASolute 302 (2026): first targeted therapy to nearly double survival in pancreatic cancer; daraxonrasib heading for approval.
- G12D-selective zoldonrasib combinations with 50% response rates in previously treated disease.
- Adjuvant mFOLFIRINOX gives median OS beyond 4 years in resected fit patients.
- High-risk surveillance shifts ~3 in 4 detected cancers to stage I in carriers.
- Personalised mRNA vaccine responders remain recurrence-free for years (autogene cevumeran phase 1).

## Open problems

- Late diagnosis; no screening.
- Dense stroma blocks drug delivery.
- Immunologically cold.
- Resistance to RAS(ON) inhibitors: secondary RAS mutations, RTK bypass, and adaptive feedback are already described; combination strategies are unproven in phase 3.
- Half of patients are too frail for FOLFIRINOX-class regimens; RAS inhibitors may change this but toxicity (rash, stomatitis) is not trivial.
- No population screening; MCED sensitivity for stage I PDAC is low and PPV in average-risk adults is poor.
- Immune exclusion: every checkpoint inhibitor trial has failed outside MSI-H disease; vaccines must overcome a cold microenvironment.
- Neoadjuvant versus upfront surgery for resectable disease remains unresolved after PREOPANC-2, NORPACT-1, and Alliance A021806.
- Cachexia and biliary obstruction limit therapy delivery; supportive care is under-studied.
- Access: RAS inhibitors and TTFields will be expensive; global disparities will widen.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pancreatic_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Pancreatic_cancer

## Connected records

- roadmaps: [Early detection roadmap: organ screening → blood tests for many cancers](https://onco.cc/roadmaps/early-detection-roadmap/), [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/)
- collections: [NHS Jewish BRCA Testing Programme](https://onco.cc/collections/nhs-jewish-brca-testing/), [PanCAN Know Your Tumor](https://onco.cc/collections/pancan-know-your-tumor/), [Pancreatic Cancer Action Network (PanCAN)](https://onco.cc/collections/pancan/), [UK specialist HPB cancer centres](https://onco.cc/collections/uk-hpb-specialist-centres/)
- ideas: [A billion-dollar prize for the first durable cure of a lethal metastatic cancer](https://onco.cc/ideas/idea-fund-cure-prize/), [A blood test for the pre-metastatic niche](https://onco.cc/ideas/idea-bio2-premetastatic-niche-assay/), [A dietitian in every gastrointestinal and head and neck tumour board](https://onco.cc/ideas/idea-nl-dietitian-in-every-mdt/), [A guaranteed purchase prize for the first drug against a named hard target](https://onco.cc/ideas/idea-bio1-undruggable-market-commitment/), [A permanent neutral non-profit sponsor for multi-company platform trials](https://onco.cc/ideas/idea-fund-neutral-platform-sponsor/), [A perpetual platform trial in every major cancer, funded as infrastructure](https://onco.cc/ideas/idea-tr2-perpetual-platforms/), [A ring-fenced metastasis programme with metastasis-specific endpoints](https://onco.cc/ideas/idea-fund-metastasis-moonshot/), [A standing platform trial for every major cancer, funded as infrastructure](https://onco.cc/ideas/idea-tr1-standing-platform-per-cancer/), [A trial of GLP-1 weight-loss drugs with cancer as the primary outcome](https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/), [AI that spots pancreatic cancer on scans taken a year before diagnosis](https://onco.cc/ideas/idea-prev-pancreas-ai-prediagnostic-ct/), [Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere](https://onco.cc/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/), [Automatic germline testing for every cancer type where it changes care](https://onco.cc/ideas/idea-prev-reflex-germline-testing/), [Automatic palliative care referral triggered by diagnosis, not by decline](https://onco.cc/ideas/idea-acc-automatic-early-palliative-triggers/), [Block the complement signal that recruits tumour-protecting cells](https://onco.cc/ideas/idea-bio2-complement-c5ar-blockade/), [Blood-based pancreatic cancer detection in new-onset diabetes](https://onco.cc/ideas/idea-mced-new-onset-diabetes/), [Break the neutrophil DNA nets that catch tumour cells after surgery](https://onco.cc/ideas/idea-bio2-net-blockade-perioperative/), [Burden-weighted portfolio targets for every major cancer funder](https://onco.cc/ideas/idea-fund-burden-weighted-portfolio/), [Can MYC be drugged directly, and will patients tolerate it?](https://onco.cc/ideas/idea-drugging-myc/), [Catch wasting early with a smart scale and a step counter](https://onco.cc/ideas/idea-bio2-remote-weight-step-monitoring/), [Clear the suppressive neutrophils out of pancreatic tumours first](https://onco.cc/ideas/idea-bio2-cxcr2-neutrophil-blockade/), [Combine the new anti-wasting antibody with exercise and protein](https://onco.cc/ideas/idea-bio2-gdf15-plus-exercise/), [Competing sponsors share one control arm in the same indication](https://onco.cc/ideas/idea-tr1-shared-control-arms-across-sponsors/), [Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide](https://onco.cc/ideas/idea-reg-olanzapine-cachexia-global-confirmation/), [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [Coverage-with-evidence registries for MR-guided and adaptive radiotherapy](https://onco.cc/ideas/idea-fund-adaptive-radiotherapy-evidence/), [Cure-focused prizes: pay for verified long-term cures, not for drugs](https://onco.cc/ideas/idea-moon-cure-prizes/), [Cut the nerve supply to tumours with old drugs](https://onco.cc/ideas/idea-nerve-tumour-blockade/), [De-acidify the tumour so T cells can work in it](https://onco.cc/ideas/idea-bio2-lactate-acid-axis/), [Dedicated cohorts for patients with performance status 2 in first-line trials](https://onco.cc/ideas/idea-tr1-ecog-2-dedicated-cohorts/), [Engineered bacteria that live in tumours and manufacture drugs there](https://onco.cc/ideas/idea-bio2-engineered-bacteria-payloads/), [Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway](https://onco.cc/ideas/idea-prev-opportunistic-ct-ai-registry/), [FAP theranostics as a pan-cancer stromal strategy](https://onco.cc/ideas/idea-fap-theranostics-pancancer/), [FAPI PET as the workup for MCED positives](https://onco.cc/ideas/idea-mced-plus-fapi/), [Four weeks of training and nutrition before major cancer surgery, as standard](https://onco.cc/ideas/idea-bio2-prehabilitation-standard/), [Get the one approved appetite drug licensed beyond a single country](https://onco.cc/ideas/idea-bio2-anamorelin-access/), [Glucose monitor data as an early pancreatic cancer signal](https://onco.cc/ideas/idea-prev-cgm-glycaemic-drift-pancreas/), [Grow each trial patient's tumour as organoids to decide which platform arm opens next](https://onco.cc/ideas/idea-tr2-organoid-coclinical-arms/), [In vivo CAR-T against solid-tumour antigens](https://onco.cc/ideas/idea-in-vivo-car-solid/), [Link bariatric and GLP-1 registries to cancer registries in every country that has both](https://onco.cc/ideas/idea-nl-bariatric-cancer-registry-linkage/), [Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3](https://onco.cc/ideas/idea-reg-losartan-pancreatic-stroma/), [Make bespoke mouse cancer models in weeks with in vivo gene editing](https://onco.cc/ideas/idea-bio1-somatic-crispr-gemms/), [Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours](https://onco.cc/ideas/idea-moon-cold-to-hot-programme/), [Match therapy to the type of scar-forming cell in the tumour](https://onco.cc/ideas/idea-bio2-caf-subtype-assignment/), [mRNA-delivered MYC decoy proteins instead of MYC inhibitors](https://onco.cc/ideas/idea-bio1-omomyc-mrna/), [New diabetes after 50 plus weight loss triggers a pancreatic cancer check](https://onco.cc/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/), [Off-the-shelf KRAS vaccines after pancreatic cancer surgery](https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/), [Partial lottery funding for good proposals in under-funded cancers](https://onco.cc/ideas/idea-fund-neglected-cancer-lottery/), [Personalised cancer vaccines at commodity cost through fully automated manufacturing](https://onco.cc/ideas/idea-moon-neoantigen-vaccines-at-scale/), [Personalised vaccines given only when the blood test turns positive](https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/), [Public risk-adjusted outcome reporting for cancer surgery to drive centralisation](https://onco.cc/ideas/idea-fund-surgical-outcomes-public-reporting/), [Rapid diagnostic centres for people with vague but worrying symptoms](https://onco.cc/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/), [RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable](https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/), [Reprogramme suppressive macrophages instead of trying to delete them](https://onco.cc/ideas/idea-bio2-trem2-myeloid-reprogramming/), [Select cachexia trial patients by the hormone driving their wasting](https://onco.cc/ideas/idea-bio2-gdf15-stratified-enrolment/), [Shared concurrent control arms across sponsors' trials in the same setting](https://onco.cc/ideas/idea-tr2-shared-control-network/), [Soften the tissue that new metastases need in order to grow](https://onco.cc/ideas/idea-bio2-matrix-stiffness-prevention/), [Stop watching stable low-risk pancreatic cysts after five years](https://onco.cc/ideas/idea-prev-ipmn-surveillance-stop-rule/), [Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere](https://onco.cc/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/), [Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles](https://onco.cc/ideas/idea-moon-cachexia-as-treatable-disease/), [Treat cachexia before it starts](https://onco.cc/ideas/idea-cachexia-gdf15-prevention/), [Zebrafish avatars for a drug answer within a week](https://onco.cc/ideas/idea-bio1-zebrafish-avatars/)
- technologies: [Bacterial vector cancer vaccines](https://onco.cc/technologies/bacterial-vector-vaccines/), [Bariatric surgery and cancer incidence](https://onco.cc/technologies/bariatric-surgery-cancer-incidence/), [Biliary stenting and drainage](https://onco.cc/technologies/biliary-stenting-drainage/), [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Cancer neuroscience: cutting the nerve supply](https://onco.cc/technologies/nerve-tumour-denervation/), [Cancer-associated thrombosis prevention and treatment](https://onco.cc/technologies/cancer-associated-thrombosis/), [CAR-T against stroma: fibroblasts and myeloid cells](https://onco.cc/technologies/stroma-directed-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Carbon-ion synchrotrons and facilities](https://onco.cc/technologies/carbon-ion-synchrotrons/), [Carbon-ion therapy](https://onco.cc/technologies/carbon-ion/), [CD40 agonist antibodies](https://onco.cc/technologies/cd40-agonists/), [CT body composition and sarcopenia measurement](https://onco.cc/technologies/ct-body-composition-sarcopenia/), [CyberKnife robotic radiosurgery](https://onco.cc/technologies/cyberknife/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [DPYD genotyping and DPD phenotyping before fluoropyrimidines](https://onco.cc/technologies/dpyd-genotyping/), [Dual-energy and spectral CT](https://onco.cc/technologies/dual-energy-spectral-ct/), [Early integrated palliative care](https://onco.cc/technologies/palliative-care/), [Elastography and contrast-enhanced ultrasound](https://onco.cc/technologies/ultrasound-elastography-ceus/), [Electrochemotherapy devices (Cliniporator)](https://onco.cc/technologies/electrochemotherapy-devices/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [Engineered bacteria as living cancer drugs](https://onco.cc/technologies/engineered-bacteria-therapy/), [Engineered exosomes as drug carriers](https://onco.cc/technologies/exosome-therapeutics/), [Enhanced recovery (ERAS) and perioperative nutrition](https://onco.cc/technologies/eras-perioperative-nutrition/), [Enteral and parenteral nutrition support](https://onco.cc/technologies/enteral-parenteral-nutrition/), [FAPI PET](https://onco.cc/technologies/fapi-pet/), [Fish oil (EPA) for cancer weight loss](https://onco.cc/technologies/omega3-epa-cachexia/), [Focused ultrasound & histotripsy](https://onco.cc/technologies/hifu-histotripsy/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Genetically engineered mouse models](https://onco.cc/technologies/genetically-engineered-mouse-models/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Gerson therapy, coffee enemas and 'detox' regimens](https://onco.cc/technologies/gerson-therapy-detox-regimens/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/), [High-dose intravenous vitamin C](https://onco.cc/technologies/high-dose-vitamin-c/), [High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/), [HIPEC perfusion pumps and PIPAC nebulisers](https://onco.cc/technologies/hipec-pipac-devices/), [HRD genomic scar scores (GIS, LOH, HRDetect)](https://onco.cc/technologies/hrd-genomic-scar-scores/), [Hypoxia-activated prodrugs](https://onco.cc/technologies/hypoxia-activated-therapy/), [Immunonutrition before cancer surgery](https://onco.cc/technologies/immunonutrition-perioperative/), [Intraoperative radiotherapy (IORT)](https://onco.cc/technologies/intraoperative-radiotherapy/), [Irreversible electroporation (NanoKnife)](https://onco.cc/technologies/irreversible-electroporation/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Mistletoe extracts (Iscador, Helixor)](https://onco.cc/technologies/mistletoe-extracts/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [MRI](https://onco.cc/technologies/mri/), [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [PDAC organoid pharmacotyping](https://onco.cc/technologies/pdac-organoid-pharmacotyping/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [Photon-counting CT](https://onco.cc/technologies/photon-counting-ct/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Red and processed meat reduction](https://onco.cc/technologies/red-processed-meat-reduction/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)](https://onco.cc/technologies/respiratory-gating-tumour-tracking-systems/), [Respiratory motion management (4D-CT, gating, breath-hold, tracking)](https://onco.cc/technologies/respiratory-motion-management/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/), [Solid stress and tumour mechanobiology models](https://onco.cc/technologies/tumour-mechanics-models/), [Surgical robots: da Vinci, Hugo, Versius and single-port systems](https://onco.cc/technologies/surgical-robot-platforms/), [Targeting the tumour's own microbes](https://onco.cc/technologies/tumour-microbiome-targeting/), [Targeting tumour mechanics and pressure](https://onco.cc/technologies/mechanobiology-therapy/), [Tumour treating fields (TTFields)](https://onco.cc/technologies/ttfields/), [UGT1A1 genotyping before irinotecan](https://onco.cc/technologies/ugt1a1-genotyping/), [Ultra-processed food and sugar-sweetened drinks](https://onco.cc/technologies/ultra-processed-food-ssb/), [Ultrasound](https://onco.cc/technologies/ultrasound/)
- targets: [ACVR1B](https://onco.cc/targets/acvr1b/), [ACVR2A](https://onco.cc/targets/acvr2a/), [Adenosine A2A receptor (ADORA2A)](https://onco.cc/targets/adora2a/), [ALPK1](https://onco.cc/targets/alpk1/), [ARHGAP5](https://onco.cc/targets/arhgap5/), [ATG12](https://onco.cc/targets/atg12/), [ATG7](https://onco.cc/targets/atg7/), [ATXN1L](https://onco.cc/targets/atxn1l/), [BCORL1](https://onco.cc/targets/bcorl1/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [CD39 (ENTPD1)](https://onco.cc/targets/entpd1/), [CD40](https://onco.cc/targets/cd40/), [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/), [CDH10](https://onco.cc/targets/cdh10/), [CDKN2B](https://onco.cc/targets/cdkn2b/), [CIC](https://onco.cc/targets/cic/), [CIP2A](https://onco.cc/targets/cip2a/), [Claudin 18.2](https://onco.cc/targets/cldn18-2/), [COL1A1](https://onco.cc/targets/col1a1/), [COL6A6](https://onco.cc/targets/col6a6/), [CSF1R](https://onco.cc/targets/csf1r/), [CTNNA2](https://onco.cc/targets/ctnna2/), [CTNND2](https://onco.cc/targets/ctnnd2/), [CUX1](https://onco.cc/targets/cux1/), [DAXX](https://onco.cc/targets/daxx/), [DCC](https://onco.cc/targets/dcc/), [DCLK1](https://onco.cc/targets/dclk1/), [DNA polymerase alpha (POLA1)](https://onco.cc/targets/pola1/), [DROSHA](https://onco.cc/targets/drosha/), [EpCAM](https://onco.cc/targets/epcam/), [ETV1](https://onco.cc/targets/etv1/), [ETV4](https://onco.cc/targets/etv4/), [ETV5](https://onco.cc/targets/etv5/), [FAK (PTK2)](https://onco.cc/targets/fak/), [FAM135B](https://onco.cc/targets/fam135b/), [FANCC](https://onco.cc/targets/fancc/), [FAP](https://onco.cc/targets/fap/), [FAT1](https://onco.cc/targets/fat1/), [FAT3](https://onco.cc/targets/fat3/), [FBLN2](https://onco.cc/targets/fbln2/), [FBXW7](https://onco.cc/targets/fbxw7/), [FCRL4](https://onco.cc/targets/fcrl4/), [FMN2](https://onco.cc/targets/fmn2/), [GNAS](https://onco.cc/targets/gnas/), [GRIN2A](https://onco.cc/targets/grin2a/), [HER3](https://onco.cc/targets/her3/), [HSPB1](https://onco.cc/targets/hspb1/), [IGF2](https://onco.cc/targets/igf2/), [IRS4](https://onco.cc/targets/irs4/), [KDM5C](https://onco.cc/targets/kdm5c/), [KDM6A](https://onco.cc/targets/kdm6a/), [KMT2C](https://onco.cc/targets/kmt2c/), [KRAS](https://onco.cc/targets/kras/), [LATS1](https://onco.cc/targets/lats1/), [LPA](https://onco.cc/targets/lpa/), [LRP1B](https://onco.cc/targets/lrp1b/), [MAP2K4](https://onco.cc/targets/map2k4/), [MARK2](https://onco.cc/targets/mark2/), [Mesothelin](https://onco.cc/targets/mesothelin/), [MIR218-1](https://onco.cc/targets/mir218-1/), [MUC16 (CA-125)](https://onco.cc/targets/muc16/), [NCOA1](https://onco.cc/targets/ncoa1/), [NFATC2](https://onco.cc/targets/nfatc2/), [NOTCH3](https://onco.cc/targets/notch3/), [NPRL2](https://onco.cc/targets/nprl2/), [NQO1](https://onco.cc/targets/nqo1/), [NR4A2](https://onco.cc/targets/nr4a2/), [NTRK](https://onco.cc/targets/ntrk/), [PALB2](https://onco.cc/targets/palb2/), [PARP](https://onco.cc/targets/parp/), [PEG3](https://onco.cc/targets/peg3/), [POLD1](https://onco.cc/targets/pold1/), [PREX2](https://onco.cc/targets/prex2/), [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/), [PTPN13](https://onco.cc/targets/ptpn13/), [PTPN3](https://onco.cc/targets/ptpn3/), [PTPRD](https://onco.cc/targets/ptprd/), [PTPRT](https://onco.cc/targets/ptprt/), [RABL3](https://onco.cc/targets/rabl3/), [RBM10](https://onco.cc/targets/rbm10/), [Ribonucleotide reductase (RRM1)](https://onco.cc/targets/rrm1/), [RNF43](https://onco.cc/targets/rnf43/), [RRM2](https://onco.cc/targets/rrm2/), [SETD1B](https://onco.cc/targets/setd1b/), [SETD2](https://onco.cc/targets/setd2/), [SETDB1](https://onco.cc/targets/setdb1/), [SF3B1](https://onco.cc/targets/sf3b1/), [SHP2 (PTPN11)](https://onco.cc/targets/shp2/), [SIRT1](https://onco.cc/targets/sirt1/), [SLC29A1](https://onco.cc/targets/slc29a1/), [SMAD3](https://onco.cc/targets/smad3/), [SMAD4](https://onco.cc/targets/smad4/), [SMARCA4](https://onco.cc/targets/smarca4/), [STK11](https://onco.cc/targets/stk11/), [TGFBR2](https://onco.cc/targets/tgfbr2/), [Thymidylate synthase (TYMS)](https://onco.cc/targets/tyms/), [Tissue factor](https://onco.cc/targets/tissue-factor/), [TNC](https://onco.cc/targets/tnc/), [TSC2](https://onco.cc/targets/tsc2/), [U2AF1](https://onco.cc/targets/u2af1/), [VHL](https://onco.cc/targets/vhl/), [VISTA](https://onco.cc/targets/vista/), [WT1](https://onco.cc/targets/wt1/), [ZNF521](https://onco.cc/targets/znf521/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Aldoxorubicin](https://onco.cc/drugs/aldoxorubicin/), [Algenpantucel-L](https://onco.cc/drugs/algenpantucel-l/), [Anetumab ravtansine](https://onco.cc/drugs/anetumab-ravtansine/), [Atebimetinib](https://onco.cc/drugs/atebimetinib/), [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/), [AZD4360](https://onco.cc/drugs/azd4360/), [AZD5863](https://onco.cc/drugs/azd5863/), [BRACAnalysis CDx](https://onco.cc/drugs/bracanalysis-cdx/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Catumaxomab](https://onco.cc/drugs/catumaxomab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [CT3001](https://onco.cc/drugs/ct3001/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Devimistat](https://onco.cc/drugs/devimistat/), [E-EDV-D682](https://onco.cc/drugs/e-edv-d682/), [ELI-002 7P](https://onco.cc/drugs/eli-002-7p/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Elraglusib](https://onco.cc/drugs/elraglusib/), [Erlotinib](https://onco.cc/drugs/erlotinib/), [Eryaspase](https://onco.cc/drugs/eryaspase/), [Evofosfamide](https://onco.cc/drugs/evofosfamide/), [FAP-2286 (177Lu / 68Ga)](https://onco.cc/drugs/fap-2286/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Galleri](https://onco.cc/drugs/galleri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [GFH375](https://onco.cc/drugs/gfh375/), [Gotistobart](https://onco.cc/drugs/gotistobart/), [IBI343](https://onco.cc/drugs/ibi343/), [IN10018](https://onco.cc/drugs/in10018/), [INCB161734](https://onco.cc/drugs/incb161734/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Ivospemin](https://onco.cc/drugs/ivospemin/), [JK08](https://onco.cc/drugs/jk08/), [JMT203](https://onco.cc/drugs/jmt203/), [JYP0015](https://onco.cc/drugs/jyp0015/), [Larotrectinib](https://onco.cc/drugs/larotrectinib/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [LM-108](https://onco.cc/drugs/lm-108/), [LP-184](https://onco.cc/drugs/lp-184/), [Mavrostobart](https://onco.cc/drugs/mavrostobart/), [Mitazalimab](https://onco.cc/drugs/mitazalimab/), [MRTX1133](https://onco.cc/drugs/mrtx1133/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/), [Navlimetostat](https://onco.cc/drugs/navlimetostat/), [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/), [NUV-1511](https://onco.cc/drugs/nuv-1511/), [Olaparib](https://onco.cc/drugs/olaparib/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pamrevlumab](https://onco.cc/drugs/pamrevlumab/), [PBP1510](https://onco.cc/drugs/pbp1510/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Ponsegromab](https://onco.cc/drugs/ponsegromab/), [QLS31905](https://onco.cc/drugs/qls31905/), [Quemliclustat](https://onco.cc/drugs/quemliclustat/), [Satricabtagene autoleucel](https://onco.cc/drugs/satricabtagene-autoleucel/), [Setidegrasib](https://onco.cc/drugs/setidegrasib/), [Sitneprotafib](https://onco.cc/drugs/sitneprotafib/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Spevatamig](https://onco.cc/drugs/spevatamig/), [Streptozocin](https://onco.cc/drugs/streptozocin/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/), [TNG462](https://onco.cc/drugs/tng462/), [TQB2868](https://onco.cc/drugs/tqb2868/), [Trabedersen](https://onco.cc/drugs/trabedersen/), [VB15010](https://onco.cc/drugs/vb15010/), [VS-7375](https://onco.cc/drugs/vs-7375/), [XNW27011](https://onco.cc/drugs/xnw27011/), [Zalifrelimab](https://onco.cc/drugs/zalifrelimab/), [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [A2 Biotherapeutics](https://onco.cc/companies/a2-biotherapeutics/), [AB Science](https://onco.cc/companies/ab-science/), [Actuate Therapeutics](https://onco.cc/companies/actuate-therapeutics/), [Adventris Pharmaceuticals](https://onco.cc/companies/adventris-pharmaceuticals/), [Alpha Tau Medical](https://onco.cc/companies/alpha-tau-medical/), [Amplia Therapeutics](https://onco.cc/companies/amplia-therapeutics/), [AngioDynamics](https://onco.cc/companies/angiodynamics/), [Anocca](https://onco.cc/companies/anocca/), [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/), [Artios Pharma](https://onco.cc/companies/artios-pharma/), [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Australasian Gastro-Intestinal Trials Group](https://onco.cc/companies/agitg/), [BioLineRx](https://onco.cc/companies/biolinerx/), [BioNTech](https://onco.cc/companies/biontech/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Capnomed (Reger Medizintechnik)](https://onco.cc/companies/capnomed/), [CARsgen Therapeutics](https://onco.cc/companies/carsgen/), [CEBIOTEX](https://onco.cc/companies/cebiotex/), [CivaTech Oncology](https://onco.cc/companies/civatech-oncology/), [ClearNote Health](https://onco.cc/companies/clearnote-health/), [Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)](https://onco.cc/companies/cornerstone-pharmaceuticals/), [Crinetics Pharmaceuticals](https://onco.cc/companies/crinetics-pharmaceuticals/), [Diakonos Oncology](https://onco.cc/companies/diakonos-oncology/), [Dutch Pancreatic Cancer Group](https://onco.cc/companies/dpcg/), [Elicio Therapeutics](https://onco.cc/companies/elicio-therapeutics/), [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/), [FibroGen](https://onco.cc/companies/fibrogen/), [Frontier Medicines](https://onco.cc/companies/frontier-medicines/), [Fujirebio](https://onco.cc/companies/fujirebio/), [GERCOR](https://onco.cc/companies/gercor/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [Halozyme Therapeutics](https://onco.cc/companies/halozyme/), [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/), [Immuneering](https://onco.cc/companies/immuneering/), [Insilico Medicine](https://onco.cc/companies/insilico-medicine/), [InxMed](https://onco.cc/companies/inxmed/), [Ipsen](https://onco.cc/companies/ipsen/), [Isarna Therapeutics](https://onco.cc/companies/isarna-therapeutics/), [Kumquat Biosciences](https://onco.cc/companies/kumquat-biosciences/), [Lisata Therapeutics](https://onco.cc/companies/lisata/), [Marker Therapeutics](https://onco.cc/companies/marker-therapeutics/), [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/), [Medigene](https://onco.cc/companies/medigene/), [Merrimack Pharmaceuticals](https://onco.cc/companies/merrimack-pharmaceuticals/), [Molecular Partners](https://onco.cc/companies/molecular-partners/), [NewLink Genetics (now Lumos Pharma)](https://onco.cc/companies/newlink-genetics/), [Novocure](https://onco.cc/companies/novocure/), [Nuvation Bio](https://onco.cc/companies/nuvation-bio/), [Oncolytics Biotech](https://onco.cc/companies/oncolytics-biotech/), [Orion, Orion Pharma](https://onco.cc/companies/orion-orion-pharma/), [Phaxiam Therapeutics (formerly ERYtech Pharma)](https://onco.cc/companies/phaxiam/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/), [Quanta Therapeutics](https://onco.cc/companies/quanta-therapeutics/), [Revolution Medicines](https://onco.cc/companies/revolution-medicines/), [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/), [SOFIE Biosciences](https://onco.cc/companies/sofie-biosciences/), [Sorrento Therapeutics](https://onco.cc/companies/sorrento-therapeutics/), [TaiRx](https://onco.cc/companies/tairx/), [Takara Bio](https://onco.cc/companies/takara-bio/), [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/), [Threshold Pharmaceuticals](https://onco.cc/companies/threshold-pharmaceuticals/), [Valar Labs](https://onco.cc/companies/valar-labs/), [Verastem Oncology](https://onco.cc/companies/verastem/), [ViewRay (MRIdian)](https://onco.cc/companies/viewray/)
- pathways: [Autophagy](https://onco.cc/pathways/autophagy/), [Cancer cachexia](https://onco.cc/pathways/cachexia-biology/), [Cancer neuroscience (nerve-tumour signalling)](https://onco.cc/pathways/cancer-neuroscience/), [DNA damage response & homologous recombination](https://onco.cc/pathways/ddr/), [Double-strand break repair: HR versus end joining](https://onco.cc/pathways/homologous-recombination-repair/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/), [Fibroblast activation, desmoplasia & matrix stiffness](https://onco.cc/pathways/caf-activation-desmoplasia/), [Glutamine addiction](https://onco.cc/pathways/glutamine-metabolism/), [Invasion: proteases, adhesion & the invasive front](https://onco.cc/pathways/invasion-ecm-degradation/), [Microbiome-tumour interactions](https://onco.cc/pathways/microbiome-tumour/), [MYC](https://onco.cc/pathways/myc/), [Pancreatic cancer (KEGG map)](https://onco.cc/pathways/pancreatic-cancer-signalling/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [Adenocarcinoma](https://onco.cc/terms/adenocarcinoma/), [Biliary drainage routes: ERCP stent, percutaneous (PTC) and EUS-guided](https://onco.cc/terms/biliary-drainage-routes/), [CA 19-9](https://onco.cc/terms/ca19-9/), [Cancer cachexia](https://onco.cc/terms/cachexia/), [Desmoplasia (tumour stroma)](https://onco.cc/terms/desmoplasia/), [Downstaging and conversion therapy](https://onco.cc/terms/downstaging/), [Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction](https://onco.cc/terms/duodenal-stenting-gastric-outlet/), [Endoscopy (EGD, EUS, ERCP)](https://onco.cc/terms/endoscopy/), [Fiducial markers](https://onco.cc/terms/fiducial-markers/), [FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX](https://onco.cc/terms/folfox-family/), [Germline BRCA mutation (gBRCA)](https://onco.cc/terms/gbrca-mutation/), [Hazard ratio (HR)](https://onco.cc/terms/hazard-ratio/), [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Mechanical theory: stiffness, pressure and force as causes](https://onco.cc/terms/mechanical-theory-of-cancer/), [Metabolic syndrome and insulin resistance](https://onco.cc/terms/metabolic-syndrome/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Nutrition impact symptoms](https://onco.cc/terms/nutrition-impact-symptoms/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/), [Obstructive jaundice and biliary obstruction](https://onco.cc/terms/obstructive-jaundice/), [Perineural invasion (PNI)](https://onco.cc/terms/perineural-invasion/), [Peritoneum and peritoneal metastases](https://onco.cc/terms/peritoneum/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Retroperitoneum](https://onco.cc/terms/retroperitoneum/), [Stenting (biliary, oesophageal, airway)](https://onco.cc/terms/biliary-stent/), [Stroma-rich and desmoplastic tumours in molecular data](https://onco.cc/terms/desmoplastic-stroma-rich/), [Symptom control in advanced gallbladder cancer: pain, ascites and nutrition](https://onco.cc/terms/gallbladder-cancer-symptom-control/), [Tumour marker](https://onco.cc/terms/tumour-marker/), [Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/)
- trials: [[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07432633/), [[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07702292/), [64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer](https://onco.cc/trials/nct06298916/), [A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)](https://onco.cc/trials/nct06428409/), [A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)](https://onco.cc/trials/nct06962267/), [A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N](https://onco.cc/trials/nct07255404/), [A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer](https://onco.cc/trials/nct07049055/), [A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations](https://onco.cc/trials/nct07629960/), [A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)](https://onco.cc/trials/g-hope-002/), [A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.](https://onco.cc/trials/nct07157033/), [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct06111274/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer](https://onco.cc/trials/nct07644559/), [A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06245330/), [A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07777211/), [A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.](https://onco.cc/trials/nct06008288/), [A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06361888/), [A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06953999/), [A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer](https://onco.cc/trials/nct03899636/), [A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)](https://onco.cc/trials/mountaintap-30/), [A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors](https://onco.cc/trials/nct06244771/), [A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab](https://onco.cc/trials/nct07280377/), [A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05859750/), [A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct07114315/), [A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04657068/), [A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors](https://onco.cc/trials/nct07488676/), [A Study of DM002 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06751329/), [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07172802/), [A Study of JMT203 in Patients With Cancer Cachexia](https://onco.cc/trials/nct06868849/), [A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07701486/), [A Study of MT-4561 in Patients With Various Advanced Solid Tumors](https://onco.cc/trials/nct06943521/), [A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07026279/), [A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07450859/), [A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06079346/), [A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC](https://onco.cc/trials/nct05968326/), [A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)](https://onco.cc/trials/nct02912949/), [A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer](https://onco.cc/trials/nct03816163/), [A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours](https://onco.cc/trials/nct06305247/), [A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05706129/), [A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer](https://onco.cc/trials/nct07079228/), [A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06598007/), [A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct07522073/), [A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer](https://onco.cc/trials/nct07409272/), [A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct05736731/), [A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06051695/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance](https://onco.cc/trials/nct07223047/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/), [A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors](https://onco.cc/trials/nct06399757/), [A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue](https://onco.cc/trials/nct06989437/), [A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies](https://onco.cc/trials/nct04503265/), [A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)](https://onco.cc/trials/nct06505395/), [ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer](https://onco.cc/trials/nct05355298/), [Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct06850623/), [Actuate 1801 Part 3B (elraglusib)](https://onco.cc/trials/actuate-1801/), [AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06646055/), [AMPLIFY-7P](https://onco.cc/trials/amplify-7p/), [An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.](https://onco.cc/trials/nct05884255/), [An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer](https://onco.cc/trials/nct07589569/), [ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07444541/), [Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07562152/), [AVENGER 500](https://onco.cc/trials/avenger-500/), [AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2](https://onco.cc/trials/nct06219941/), [Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen](https://onco.cc/trials/nct07087054/), [CEB-01 in Locally Resectable Pancreatic Cancer](https://onco.cc/trials/nct06538857/), [Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers](https://onco.cc/trials/nct04404595/), [Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C](https://onco.cc/trials/nct06821503/), [Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms](https://onco.cc/trials/nct06767813/), [Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct05653453/), [Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct04390399/), [CONKO-001](https://onco.cc/trials/conko-001/), [Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy](https://onco.cc/trials/nct05431270/), [Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct07627711/), [Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct07480928/), [Early Phase Study of KESONOTIDE™in Participants With Solid Tumours](https://onco.cc/trials/nct06926075/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [ESPAC-3](https://onco.cc/trials/espac-3/), [ESPAC-4](https://onco.cc/trials/espac-4/), [ESPAC-5](https://onco.cc/trials/espac-5/), [Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer](https://onco.cc/trials/nct03579836/), [Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers](https://onco.cc/trials/nct02584244/), [First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer](https://onco.cc/trials/nct05141149/), [FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma](https://onco.cc/trials/nct05466799/), [Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer](https://onco.cc/trials/nct01954992/), [HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07232875/), [HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors](https://onco.cc/trials/nct07296341/), [IBI343 in Combination Therapy for Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07483554/), [IMPRESS (algenpantucel-L)](https://onco.cc/trials/impress-trial/), [IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05827796/), [Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source](https://onco.cc/trials/nct02843945/), [Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC](https://onco.cc/trials/nct03257033/), [Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07238283/), [LAP07](https://onco.cc/trials/lap07/), [LAPIS](https://onco.cc/trials/lapis-trial/), [Lead-212 PSV359 Therapy for Patients With Solid Tumors](https://onco.cc/trials/nct06710756/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [Namodenoson Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct06387342/), [NAPOLI 3](https://onco.cc/trials/napoli-3/), [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [NORPACT-1](https://onco.cc/trials/norpact-1/), [NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)](https://onco.cc/trials/notable-trial/), [PANOVA-3](https://onco.cc/trials/panova-3/), [Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors](https://onco.cc/trials/nct07145255/), [Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma](https://onco.cc/trials/nct07529808/), [Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.](https://onco.cc/trials/nct07148128/), [Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors](https://onco.cc/trials/nct05945823/), [Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct06105021/), [Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06819215/), [Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients](https://onco.cc/trials/nct06730009/), [Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07262567/), [POLO](https://onco.cc/trials/polo/), [Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06752811/), [Ponsegromab phase 2 in cancer cachexia](https://onco.cc/trials/ponsegromab-phase-2/), [PRECEDE](https://onco.cc/trials/precede/), [Precision Promise](https://onco.cc/trials/precision-promise/), [PREOPANC-1 / PREOPANC-2](https://onco.cc/trials/preopanc/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder](https://onco.cc/trials/nct07072728/), [RASolute 302](https://onco.cc/trials/rasolute-302/), [Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer](https://onco.cc/trials/nct07006077/), [Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07259317/), [Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer](https://onco.cc/trials/nct04969731/), [Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients](https://onco.cc/trials/nct04888312/), [Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06334432/), [Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer](https://onco.cc/trials/nct07575191/), [Saltikva for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct04589234/), [Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors](https://onco.cc/trials/nct07165886/), [SL-28 for Advanced Solid Tumours](https://onco.cc/trials/nct07341737/), [Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct](https://onco.cc/trials/nct05482893/), [Study for AZD4360 in Participants With Advanced Solid Tumours](https://onco.cc/trials/nct06921928/), [Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors](https://onco.cc/trials/nct07278479/), [Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)](https://onco.cc/trials/nct06710132/), [Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06005493/), [Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct02340117/), [Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07030257/), [Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors](https://onco.cc/trials/nct03600233/), [Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07252232/), [Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07491445/), [Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06128551/), [Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations](https://onco.cc/trials/nct07640295/), [Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct06895031/), [Study of LP-184 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05933265/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer](https://onco.cc/trials/nct05254171/), [Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct06608927/), [Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors](https://onco.cc/trials/nct06445062/), [Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct05379985/), [Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors](https://onco.cc/trials/nct06040541/), [Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments](https://onco.cc/trials/nct06799637/), [Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy](https://onco.cc/trials/nct07823049/), [Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut](https://onco.cc/trials/nct07805954/), [Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta](https://onco.cc/trials/nct07621718/), [Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05985655/), [Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv](https://onco.cc/trials/nct05257993/), [Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o](https://onco.cc/trials/nct07219238/), [Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET](https://onco.cc/trials/nct06784752/), [Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET](https://onco.cc/trials/nct03972488/), [Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C](https://onco.cc/trials/nct04827953/), [Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients](https://onco.cc/trials/nct06922591/), [Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors](https://onco.cc/trials/nct05636618/), [The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct06861088/), [The KN510713 Study in Combination With mFOLFIRINOX](https://onco.cc/trials/nct07114861/), [TRYbeCA-1](https://onco.cc/trials/trybeca-1/)
- people: [Albert C. Koong](https://onco.cc/people/albert-koong/), [Andrew J. Aguirre](https://onco.cc/people/andrew-aguirre/), [Anirban Maitra](https://onco.cc/people/anirban-maitra/), [Bert Vogelstein](https://onco.cc/people/bert-vogelstein/), [Costas A. Lyssiotis](https://onco.cc/people/costas-lyssiotis/), [Daniel D. Von Hoff](https://onco.cc/people/daniel-von-hoff/), [David A. Tuveson](https://onco.cc/people/david-tuveson/), [Diane M. Simeone](https://onco.cc/people/diane-simeone/), [Do-Youn Oh](https://onco.cc/people/oh-do-youn/), [Dung T. Le](https://onco.cc/people/dung-le/), [Eileen M. O'Reilly](https://onco.cc/people/eileen-oreilly/), [Elizabeth M. Jaffee](https://onco.cc/people/elizabeth-jaffee/), [Eric Van Cutsem](https://onco.cc/people/eric-van-cutsem/), [Francisco Berrospi Espinoza](https://onco.cc/people/francisco-berrospi-espinoza/), [Frank McCormick](https://onco.cc/people/frank-mccormick/), [Giampaolo Tortora](https://onco.cc/people/giampaolo-tortora/), [Hedy L. Kindler](https://onco.cc/people/hedy-kindler/), [Jürgen Weitz](https://onco.cc/people/jurgen-weitz/), [Kevan M. Shokat](https://onco.cc/people/kevan-shokat/), [Leonor Beleza](https://onco.cc/people/leonor-beleza/), [Lin Shen](https://onco.cc/people/shen-lin/), [Linda Tantawi](https://onco.cc/people/linda-tantawi/), [Marc G. Besselink](https://onco.cc/people/marc-besselink/), [Marc Lustgarten](https://onco.cc/people/marc-lustgarten/), [Matthew Vander Heiden](https://onco.cc/people/matthew-vander-heiden/), [Owen Sansom](https://onco.cc/people/owen-sansom/), [Peter J. O'Dwyer](https://onco.cc/people/peter-odwyer/), [Peter W. T. Pisters](https://onco.cc/people/peter-pisters/), [Philip D. Greenberg](https://onco.cc/people/philip-greenberg/), [Raffit Hassan](https://onco.cc/people/raffit-hassan/), [Randy Pausch](https://onco.cc/people/randy-pausch/), [Richard Schulick](https://onco.cc/people/richard-schulick/), [Robert H. Vonderheide](https://onco.cc/people/robert-vonderheide/), [Selwyn M. Vickers](https://onco.cc/people/selwyn-vickers/), [Senthil K. Muthuswamy](https://onco.cc/people/senthil-muthuswamy/), [Susan M. Domchek](https://onco.cc/people/susan-domchek/), [Talia Golan](https://onco.cc/people/talia-golan/), [Tanios Bekaii-Saab](https://onco.cc/people/tanios-bekaii-saab/), [Teresa Cotta-Dias](https://onco.cc/people/teresa-cotta-dias/), [Theodore S. Hong](https://onco.cc/people/theodore-hong/), [Theodore S. Lawrence](https://onco.cc/people/theodore-lawrence/), [Thierry Conroy](https://onco.cc/people/thierry-conroy/), [Tobias Janowitz](https://onco.cc/people/tobias-janowitz/), [Uğur Şahin](https://onco.cc/people/ugur-sahin/), [Vinod P. Balachandran](https://onco.cc/people/vinod-balachandran/), [Volker Heinemann](https://onco.cc/people/volker-heinemann/), [Zev A. Wainberg](https://onco.cc/people/zev-wainberg/)
- key papers: [Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014](https://onco.cc/key-papers/paper-allemani-concord-3-lancet-2018/), [Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/), [Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)](https://onco.cc/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/), [Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer](https://onco.cc/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/), [Calle 2003: overweight, obesity and death from cancer in 900,000 US adults](https://onco.cc/key-papers/paper-calle-obesity-cancer-mortality-nejm-2003/), [Chmielecki 2014: comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes](https://onco.cc/key-papers/paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014/), [CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer](https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/), [CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer](https://onco.cc/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/), [Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)](https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/), [Dhebri 2004: diagnosis, treatment and outcome of pancreatoblastoma](https://onco.cc/key-papers/paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004/), [Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02](https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/), [eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer](https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/), [ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection](https://onco.cc/key-papers/paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010/), [ESPAC-4: adjuvant gemcitabine and capecitabine versus gemcitabine monotherapy in resected pancreatic cancer](https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-neoptolemos-lancet-2017/), [ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer](https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/), [ESPAC-5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy in borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-ghaneh-lancet-gastroenterol-hepatol-2023/), [ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/), [European evidence-based guidelines on pancreatic cystic neoplasms (2018)](https://onco.cc/key-papers/paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018/), [Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back](https://onco.cc/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/), [Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer](https://onco.cc/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/), [Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations](https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/), [IARC verdict: excess body fat causes 13 cancers](https://onco.cc/key-papers/paper-body-fatness-iarc-nejm-2016/), [International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)](https://onco.cc/key-papers/paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024/), [Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/), [KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer](https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/), [Klimstra 1992: acinar cell carcinoma of the pancreas, a clinicopathologic study of 28 cases](https://onco.cc/key-papers/paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992/), [Klimstra 1995: pancreatoblastoma, a clinicopathologic study and review of the literature](https://onco.cc/key-papers/paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995/), [KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer](https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/), [La Rosa 2012: clinicopathologic study of 62 acinar cell carcinomas of the pancreas](https://onco.cc/key-papers/paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012/), [LAP07: chemoradiotherapy versus chemotherapy after four months of gemcitabine in locally advanced pancreatic cancer](https://onco.cc/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-hammel-jama-2016/), [LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine](https://onco.cc/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016/), [Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval](https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/), [MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer](https://onco.cc/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/), [NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer](https://onco.cc/key-papers/paper-napoli-3-lancet-2023/), [NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer](https://onco.cc/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/), [O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation](https://onco.cc/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/), [Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable](https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/), [Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial](https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/), [POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/), [POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/), [PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/), [PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer](https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/), [Rahib 2014: projecting US cancer incidence and deaths to 2030](https://onco.cc/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/), [Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)](https://onco.cc/key-papers/paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017/), [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/), [Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report](https://onco.cc/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/), [Wisnoski 2008: 672 patients with acinar cell carcinoma of the pancreas, a population-based comparison to pancreatic adenocarcinoma](https://onco.cc/key-papers/paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008/)
- journals: [Clinical colorectal cancer](https://onco.cc/journals/clinical-colorectal-cancer/), [Journal of gastrointestinal cancer](https://onco.cc/journals/journal-of-gastrointestinal-cancer/)
- pairings: [G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)](https://onco.cc/pairings/g12d-plus-pan-ras/), [Personalised neoantigen vaccine + PD-1 blockade](https://onco.cc/pairings/vaccine-plus-pd1/)
- institutions: [Addenbrooke's Hospital, Cambridge University Hospitals](https://onco.cc/institutions/addenbrookes-cambridge/), [Amsterdam UMC / Cancer Center Amsterdam](https://onco.cc/institutions/amsterdam-umc/), [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [Beatson West of Scotland Cancer Centre / CRUK Scotland Institute](https://onco.cc/institutions/beatson-glasgow/), [Belfast Health and Social Care Trust HPB service](https://onco.cc/institutions/belfast-trust-hpb/), [Cedars-Sinai Cancer](https://onco.cc/institutions/cedars-sinai-cancer/), [Centro Nacional de Investigaciones Oncológicas (CNIO)](https://onco.cc/institutions/cnio/), [Champalimaud Foundation, Champalimaud Clinical Centre](https://onco.cc/institutions/champalimaud/), [Cold Spring Harbor Laboratory](https://onco.cc/institutions/cold-spring-harbor/), [Derriford Hospital, University Hospitals Plymouth](https://onco.cc/institutions/derriford-plymouth/), [Fred & Pamela Buffett Cancer Center](https://onco.cc/institutions/nebraska-buffett/), [Garvan Institute of Medical Research / Kinghorn Cancer Centre](https://onco.cc/institutions/garvan-institute/), [Glasgow Royal Infirmary](https://onco.cc/institutions/glasgow-royal-infirmary/), [Gunma University Heavy Ion Medical Center](https://onco.cc/institutions/gunma-heavy-ion-medical-center/), [Holden Comprehensive Cancer Center, University of Iowa](https://onco.cc/institutions/iowa-holden/), [INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia](https://onco.cc/institutions/incliva-valencia/), [Institut Paoli-Calmettes](https://onco.cc/institutions/institut-paoli-calmettes/), [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/), [King's College Hospital, London](https://onco.cc/institutions/kings-college-hospital-london/), [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/), [Liverpool University Hospitals HPB centre (Aintree)](https://onco.cc/institutions/liverpool-hpb-centre/), [Lustgarten Foundation](https://onco.cc/institutions/lustgarten-foundation/), [Manchester Royal Infirmary HPB Unit](https://onco.cc/institutions/manchester-royal-infirmary/), [Mayo Clinic Comprehensive Cancer Center in Arizona](https://onco.cc/institutions/mayo-clinic-arizona/), [Mays Cancer Center at UT Health San Antonio](https://onco.cc/institutions/mays-cancer-center/), [Morriston Hospital, Swansea](https://onco.cc/institutions/morriston-swansea/), [NCT/UCC Dresden, University Hospital Carl Gustav Carus](https://onco.cc/institutions/nct-dresden/), [O'Neal Comprehensive Cancer Center at UAB](https://onco.cc/institutions/oneal-uab/), [Ontario Institute for Cancer Research](https://onco.cc/institutions/oicr/), [Peking Union Medical College Hospital](https://onco.cc/institutions/pumch/), [QST Hospital (National Institutes for Quantum Science and Technology)](https://onco.cc/institutions/qst-hospital/), [Royal Infirmary of Edinburgh](https://onco.cc/institutions/royal-infirmary-edinburgh/), [Ruijin Hospital, Shanghai Jiao Tong University](https://onco.cc/institutions/ruijin-hospital/), [Salk Institute Cancer Center](https://onco.cc/institutions/salk-institute/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [Stand Up To Cancer](https://onco.cc/institutions/stand-up-to-cancer/), [Tianjin Medical University Cancer Institute and Hospital](https://onco.cc/institutions/tmucih/), [Translational Genomics Research Institute (TGen)](https://onco.cc/institutions/tgen/), [TUM Klinikum rechts der Isar / CCC München](https://onco.cc/institutions/tum-munich/), [UMC Utrecht Cancer Center](https://onco.cc/institutions/umc-utrecht/), [University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz](https://onco.cc/institutions/uct-mainz/), [University Hospital of Wales, Cardiff](https://onco.cc/institutions/university-hospital-wales-cardiff/), [UZ Leuven / Leuven Cancer Institute](https://onco.cc/institutions/uz-leuven/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Pain relief and palliative care are unavailable to most](https://onco.cc/bottlenecks/b-palliative/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [Tumour heterogeneity and clonal evolution](https://onco.cc/bottlenecks/b-tumor-heterogeneity/)
- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatoblastoma](https://onco.cc/cancers/pancreatoblastoma/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- biomarkers: [Claudin 18.2 expression (>= 75% of tumour cells, moderate to strong)](https://onco.cc/biomarkers/cldn18-2-expression/), [Germline BRCA1/2 pathogenic variant (gBRCAm)](https://onco.cc/biomarkers/brca-germline/), [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/), [KRAS G12D (and other non-G12C KRAS mutations)](https://onco.cc/biomarkers/kras-g12d/)

---
JSON: https://onco.cc/api/v1/entities/pancreatic.json